RC28-E protein clinical trials
How each study uses RC28-E protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RC28-E protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Angiogenesis inhibitors source
Studies
Open first, then newest update. How each study uses RC28-E protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- IIIb Trial for RC28-E Injection in Participants With DME and wAMDNot yet recruitingPhase 3RemeGen Co., Ltd.NCT07936487Written as RC28-E
- Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular EdemaRecruitingPhase 3RemeGen Co., Ltd.NCT05885503Written as RC-28E
- Efficacy and Safety of RC28-E Versus AfliberceptRecruitingPhase 3RemeGen Co., Ltd.NCT05727397Written as RC28-E
- Evaluation of RC28-E Injection in Diabetic RetinopathyStatus unknownPhase 2RemeGen Co., Ltd.NCT04782128Written as RC28-E injection
- Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular DegenerationCompletedPhase 1RemeGen Co., Ltd.NCT03777254Written as RC28-E
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- IIIb Trial for RC28-E Injection in Participants With DME and wAMDNov 13, 2026NCT07936487
Codes
What other systems call RC28-E protein · ClinicalTrials.gg INT001425
- MeSH (NLM) C000710674RC28-E proteinOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710674 | RC28-E protein | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.